Dear Editor, Despite recent advances in anticoagulation therapy, there are regular situations in clinical practice which are inadequately covered by current guidelines. These include situations such as obesity and long-term therapy, particularly if vitamin K antagonists (VKA) and/or heparin derivatives are inappropriate. These situations have rarely been the aim of randomised controlled trials. We present a case of successful long-term treatment with fondaparinux in a patient with a mechanical heart valve, obesity and concomitant therapy with aspirin and discuss available data in these situations.
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A 63-year-old male patient with obesity underwent aortal valve replacement with a mechanical prosthesis because of aortal stenosis. Anticoagulation with VKA was started. Six weeks postoperatively, he presented with lifethreatening bleeding. Investigations revealed factor IX propeptide mutation, which made anticoagulation with VKA impossible. This rare condition causes a nearly complete absence of factor IX during therapy with VKA, even in the presence of a mild vitamin K deficiency [1] . Therapy with low-molecular-weight heparin (LMWH) resulted in lumps at the puncture site. Failure of absorption could be seen in a gradual decrease in drug concentration measured as anti-Xa level (initially 0.9-1.0 U/ml, reduced to 0.45-0.5 U/ml), despite increasing the dose. This adverse effect was shown with dalteparin, enoxaparin and nadroparin. Anticoagulation was therefore started with fondaparinux. Due to obesity (BMI, 36 kg/m 2 ), we administered 10 mg once daily sc. During the next 30 months, stable drug concentrations measured as anti-Xa of about 1.0 μg/ml were observed. D-dimers, measured as a degree of coagulation activation, were always below 220 ng/ml. Regular controls revealed no clinical signs or symptoms of thromboembolic complications, and in particular, no neurological deficits. Computed tomography of the head as well as echocardiography did not reveal any thromboembolic complications. The patient did not experience any bleeding. Due to additional risk factors for thromboembolism, 100 mg aspirin was added to the therapy.
A high bioavailability, long elimination half life, very low intra-and intersubject variability and lack of relevant drug interactions suggest good efficacy and safety during long-term treatment [2] [3] [4] . This was confirmed in a phase III trial in the treatment of superficial vein thrombosis with fondaparinux 2.5 mg for 45 days [5] and in one prospective observational study reported on patients treated with a therapeutic dose of fondaparinux (7.5 mg) for 90 days because of deep vein thrombosis or pulmonary embolism [6] . Our report described above is by far the longest reported therapy with fondaparinux (more than 30 months up to now).
Two different models, an in vitro experiment and ex vivo rabbit model with artificial mechanical heart valves, showed comparable thrombosis rates as seen with UFH or LMWH [7, 8] . To the best of our knowledge, the patient described above is the first case report of successful longterm anticoagulation with fondaparinux in a patient with mechanical heart valve.
In conclusion, our case report confirms available data and shows that it is possible to conduct long-term anticoagulation with fondaparinux in combination with aspirin in a patient with a mechanical heart valve and obesity.
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